Fulcrum nears 2024 highs after promising sickle-cell trial results

Fulcrum Therapeutics surged over 51% in premarket trade after early Phase 1b data for its sickle-cell therapy showed strong fetal hemoglobin increases, with 58% of patients reaching HbF levels above 20%. Analysts raised targets, with Piper Sandler moving to $23 and Wainwright to $25. Retail sentiment turned extremely bullish as the stock approached 2024 highs.